Clinical Trials Directory

Trials / Unknown

UnknownNCT00407706

Using Test of SCM for Detection Breast Cancer

Breast Cancer- Early Detection of Cancer Disease and Pre-Cancer Disease, and in Women That Are at High Risk for Developing Breast Cancer by Identifying Lymphocytes Previously Exposed to Specific Cancer Antigen.

Status
Unknown
Phase
Study type
Observational
Enrollment
180 (planned)
Sponsor
Ziv Hospital · Other Government
Sex
Female
Age
18 Years – 50 Years
Healthy volunteers
Not accepted

Summary

In our previous research, we have shown that women that have breast cancer have a population of lymphocytes that recognizes specific antigen and there cytoplasmic matrix goes through physical change a short time after exposure in vitro to the same antigen. This change can be measured by polarization changes of fluorescent light emitted by FDA (fluorescein diacetate) labeled cells. Further test that we performed showed that those differences are also shown in a benign situation that known as indicator for a high risk for developing breast cancer within 10-15 years. The incidence of the expression of these lymphocytes correlates with the histopathological picture as it is related in high risk for the developing the disease. In this work we will expand the scope of the procedure to early detection of the cancerous process in breast lesions by Fitzgibbon's risk categories for the development invasive carcinoma of the breast. In the proposed work we intend to use specific antigen MUC1 for breast cancer. This study is a continuation of our published work in the "The Breast "

Conditions

Interventions

TypeNameDescription
PROCEDUREblood test

Timeline

Start date
2006-12-01
Completion
2010-12-01
First posted
2006-12-05
Last updated
2006-12-05

Locations

1 site across 1 country: Israel

Source: ClinicalTrials.gov record NCT00407706. Inclusion in this directory is not an endorsement.